Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...
1d
Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.
Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, ...
Pfizer has clinched a US$10 billion deal to acquire obesity drug developer Metsera, ending a heated bidding war with Danish ...
The stock market caters to investors with almost any budget, especially with online brokers offering commission-free trading ...
Responsible for Corporate Development, Investor Relations, Government Affairs –REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- ...
A fierce bidding war is underway between Novo Nordisk and Pfizer over Metsera’s obesity drug assets, valued at $10 billion. Despite Pfizer’s efforts to sweeten its offer before a critical deadline, ...
Pfizer is not alone among American health-care companies in feeling under the weather. Gilead Sciences, a biotech behemoth, also sold fewer drugs. GE HealthCare, a maker of fancy scanners, said net ...
Held meeting with U.S. Food and Drug Administration (FDA) where, among other things, they reiterated October 2024 agreement to use estimated ...
Britain on Wednesday became the first country in the world to approve the COVID-19 vaccine developed by U.S. drugmaker Pfizer and its German partner BioNTech , , and said it will be rolled out from ...
Novo and Pfizer are engaged in an intense bidding war for Metsera, a key player in the obesity drug market. This competition follows Novo's unexpected bid after Metsera agreed to Pfizer's acquisition, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback